The global liquid biopsy market size reached US$ 1.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 15.3% during 2023-2028. More Info:- https://www.imarcgroup.com/liquid-biopsy-market

1. Copyright © IMARC Service Pvt Ltd. All Rights Reserved
Global Liquid Biopsy Market
Research and Forecast
Report 2023-2028
Author: Elena Anderson,
Marketing Manager |
IMARC Group
© 2019 IMARC All Rights Reserved

2. Report Description
About IMARC Group
The International Market Analysis Research and Consulting Group is a leading adviser on
management strategy and market research worldwide. We partner with clients in all sectors
and regions to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. Report Description
Report Description and Highlights
Global Liquid Biopsy Market Research Report:
The latest report by IMARC, titled “Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth,
Opportunity and Forecast 2023-2028” finds that the global liquid biopsy market size reached US$ 1.8
Billion in 2022.
Liquid biopsy is a test enabling the diagnosis of cancer cells from a tumor circulating in the blood. It is a
non-invasive alternative to surgical biopsy that is efficient and faster. It can detect epidermal growth
factor receptor (EGFR) gene mutations with non-small cell lung cancer (NSCLC), which helps medical
professionals to choose a suitable treatment for patients.
In addition, it assists in identifying key genetic changes that aid in diagnosing, treating, and monitoring
periods of relapse and remission in patients.
Request Free Sample Report: https://www.imarcgroup.com/liquid-biopsy-market/requestsample

4. Report Description
Report Description and Highlights
Global Liquid Biopsy Market Trends:
The growing utilization of liquid biopsy for screening early cancer, monitoring tumor progression, assessing
therapeutic response and clinical prognosis, and detecting recurrent and refractory tumors represents one of the key
factors driving the market. Besides this, there is a rise in the number of cancer patients due to excessive tobacco
consumption and the sedentary lifestyles of individuals across the globe. This, along with increasing advancements in
liquid biopsy, such as next-generation sequencing for advanced cancer patients, is contributing to the growth of the
market.
In addition, the rising patient preference for minimally invasive therapies due to lesser tissue damage, fewer
complications, and minimal pain and scarring is propelling the growth of the market. Moreover, governments of
several countries are focusing on promoting awareness of cancer. This, coupled with the burgeoning healthcare
industry, is bolstering the growth of the market. Looking forward, IMARC Group expects the market to reach US$ 4.3
Billion by 2028, exhibiting a CAGR of 15.3% during the forecast period (2023-2028).
Looking forward, the market value is projected to reach a strong growth during the forecast period
(2023-2028).

5. Report Description
Report Description and Highlights
Market Summary:
Product And Service Insights:
• Kits and Reagents
• Platforms and Instruments
• Services
Circulating Biomarker Insights:
• Circulating Tumor Cells
• Extracellular Vesicles
• Circulating Tumor DNA
• Others
Cancer Type Insights:
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Others

6. Report Description
Report Description and Highlights
End User Insights:
• Hospitals and Laboratories
• Academic and Research Centers
• Others
Regional Insights:
• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France

7. Report Description
Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

8. Competitive Landscape with Key Players:
• ANGLE plc
• Biocept Inc.
• Bio-Rad Laboratories Inc
• Epigenomics AG
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Guardant Health Inc.
• Illumina Inc.
• MDxHealth SA
• Menarini Silicon Biosystems
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/liquid-biopsy-market
Report Description
Report Description and Highlights

9. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

10. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

11. Report Description
Report Description and Highlights
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

12. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com
https://www.imarcgroup.com
Contact Us